^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF17 amplification

    i
    Other names: TNFRSF17, TNF Receptor Superfamily Member 17, Tumor Necrosis Factor Receptor Superfamily Member 17, B-Cell Maturation Protein, BCMA, Tumor Necrosis Factor Receptor Superfamily, Member 17, B Cell Maturation Antigen, B-Cell Maturation Factor, CD269 Antigen, TNFRSF13A, CD269
    Entrez ID:
    608
    Related biomarkers:
    Expression
    CNA
    Others
    12ms
    GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A (EHA 2023)
    Genomic analysis of BMA samples from MagnetisMM-3 identified an association between higher TNFRSF17 expression in the tumor microenvironment and unfavorable outcomes, likely due to its surrogacy with increased tumor burden. Features of high-risk disease were also associated with lack of response to elranatamab. Adjusting for tumor cell content revealed additional aspects of the tumor microenvironment associated with poor response, including increased myeloid cell populations.
    IO biomarker • Omic analysis
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    TNFRSF17 expression • TNFRSF17 amplification
    |
    Elrexfio (elranatamab-bcmm)